pH-impedance monitoring for symptoms beyond heartburn

Reflux is often described as heartburn and sour regurgitation, yet some people present only with cough, throat clearing, globus, hoarseness, chest discomfort or post-prandial symptoms. Extraesophageal complaints cannot be diagnosed as reflux from symptoms alone, and airway or cardiac disease may need urgent assessment. Objective testing is most useful when uncertainty will affect management.

pH-impedance monitoring combines pH sensors with multichannel intraluminal impedance to record the acidity and movement of material within the oesophagus. It identifies acid, weakly acidic and alkaline reflux events, counts belches, assesses clearance and relates episodes to symptoms recorded in a diary. A pH study alone may miss weakly acidic reflux during acid suppression.

This distinction was relevant to the scientific programme of the virtual ISDE 2021 World Congress for Esophageal Diseases, held from 27–30 September 2021. For Australian clinicians and patients, the important issue is whether the test answers a specific question, reflects medication history and leads to proportionate care.

When pH-impedance testing adds value

pH-impedance monitoring is considered when symptoms are not typical of gastro-oesophageal reflux disease (GERD), or when regurgitation and belching dominate. It may clarify suspected reflux-related cough or throat symptoms after other causes have been considered, especially if complaints follow meals or persist despite treatment.

The test can reveal acid breakthrough, weakly acidic reflux, reflux-associated coughing or a pattern not temporally linked to reflux. It does not automatically prove that reflux causes symptoms, and its value depends on the result changing a management decision.

What the test measures

During a 24-hour ambulatory study, a transnasal catheter records usual meals, sleep and activity. Impedance detects liquid and gas boluses through changes in electrical resistance, allowing reflux events to be classified and their proximal extent and clearance assessed.

The report may include acid exposure time, reflux-event counts and symptom association index (SAI) or reflux symptom association probability (SAP). These assess whether symptoms occur close to reflux events when enough data are recorded. Association supports correlation but does not, by itself, establish causation.

Linking symptoms to reflux events

Symptom timing is more informative than an isolated abnormal number. Repeated coughing immediately after a reflux event may support a reflux mechanism; symptoms occurring hours later weaken that link. Laboratory ranges vary, so medication status and clinical probability must accompany interpretation.

Marked reflux without symptoms and troublesome symptoms without much reflux both occur. Functional reflux, reflux hypersensitivity, motility disorders, asthma and upper-airway disease remain alternatives. Chest symptoms also require consideration of non-oesophageal causes, including cardiac disease.

Australian practice and patient realities

Australian patients may first approach a general practitioner or community pharmacy. Proton-pump inhibitors are available through pharmacies, with Medicare subsidy for eligible indications; longer-term use should remain indication-led. Specialist referral is usually required for pH-impedance testing, and any proton-pump inhibitor withholding should be medically supervised.

Everyday patterns also matter. Long lunches, takeaway meals, drive-through coffee and late dining make symptom diaries useful in Sydney, Melbourne and Brisbane. Shift workers in Perth, Adelaide and regional centres need practical planning. Most medical devices used in Australia are regulated through the Therapeutic Goods Administration, while the Privacy Act 1988 and Australian Privacy Principles govern the handling of health information.

Preparing for and completing the study

Preparation aims to keep the study representative without avoidable risk. Patients usually fast briefly before insertion, complete the symptom diary and avoid specified food or drink items for a defined period. PPIs, H2 blockers and antacids may need adjustment, but only under prescriber guidance.

Do not stop prescribed medicine independently. If symptoms are severe or unstable, the clinician may defer testing. Nasal discomfort, gagging and throat irritation are common; bleeding, severe pain, fever or persistent vomiting require prompt medical review.

Recommendations for reliable testing

A dependable pathway starts with a defined clinical question:

• Specify the question, such as whether reflux likely explains persistent cough or post-prandial hoarseness, before testing.
• Record all medicines, doses and timing, especially proton-pump inhibitors, H2 blockers and antacids.
• Follow the laboratory’s fasting, meal and restricted-food instructions, and change medication only on prescriber advice.
• Log symptoms, meals, posture, coughing, belching and suspected triggers with accurate times.
• Review reflux-event burden, acid exposure time and SAI or SAP together rather than relying on one metric.
• Use the findings to guide proportionate next steps, including further assessment when reflux is not supported.

The report should be interpreted with medication changes and symptom timing clearly visible. Conflicting tests or persistent red flags warrant specialist review rather than repeated testing without a new hypothesis.

From results to a practical next step

On therapy, results may show inadequate acid control, breakthrough reflux or a mismatch between symptoms and events. Off therapy, excessive acid exposure can support GERD, while normal results may make reflux a less likely explanation. Neither report should be used as a stand-alone diagnosis.

Treatment may involve medication review, reflux precautions or further investigation, and ENT, respiratory or allergy input may help with extraesophageal symptoms. Anti-reflux surgery should not follow a diary or pH-impedance result alone. The practical takeaway is to use the study as a targeted clinical tool: interpret events alongside symptoms and medication exposure, and let a coherent clinical picture determine the next proportionate step.